Purpose of this Study
What happens in this study?
- You'll get the study medicine through an IV every 3 weeks
- Depending on your group, you might also get:
- Budigalimab (a new medicine being tested)
- Or a standard cancer medicine
- You'll give blood and urine samples
- You'll have regular CT or MRI scans to check your health
Who Can Participate?
Eligibility
Who can join this study?
- Adults who are 18 or older
- Have an advanced or spreading form of cancer called a solid tumor
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
Why is this study happening?
Doctors want to see if a new medicine called azirkitug (ABBV-514) is safe and works well for people with certain cancers that have spread. They're testing it by itself, or with other medicines like budigalimab or bevacizumab.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab (M24-410)
Principal Investigator
John
Strickler
Protocol Number
PRO00118843
NCT ID
NCT05005403
Phase
I
Enrollment Status
Pending Open to Enrollment